ISOLYTE E IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ISOLYTE E IN PLASTIC CONTAINER (ISOLYTE E IN PLASTIC CONTAINER).

How it works

ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.

What the body does with it

Metabolism	Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Excretion	Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
Half-life	Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Protein binding	Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Volume of Distribution	Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Bioavailability	Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
Onset of Action	Intravenous: Immediate (within seconds to minutes) as electrolytes and fluid are directly infused into the bloodstream.
Duration of Action	Intravenous: Duration depends on infusion rate and renal clearance; typical effects last for the duration of infusion and for 2-4 hours post-infusion for electrolyte balance.

Classification & Brands

Dosing & administration

Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 mL as a single infusion, administered at a rate of 5-10 mL/min.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in patients with severe renal impairment (GFR < 30 mL/min) due to risk of hyperkalemia. For GFR 30-50 mL/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 mL/min.
Liver impairment	Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Pediatric use	Weight-based dosing: 20-30 mL/kg as a single intravenous infusion, administered at a rate not exceeding 5 mL/kg/hour. Maximum total volume: 1000 mL. Adjust based on clinical status and serum electrolytes.
Geriatric use	Elderly patients may require reduced infusion rates (2-5 mL/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ISOLYTE E IN PLASTIC CONTAINER (ISOLYTE E IN PLASTIC CONTAINER).

Breastfeeding	ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
Teratogenic Risk	ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.

Clinical Precautions

Precautions

Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

ISOLYTE E IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ISOLYTE E IN PLASTIC CONTAINER (ISOLYTE E IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Excretion	Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
Half-life	Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Protein binding	Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Volume of Distribution	Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Bioavailability	Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
Onset of Action	Intravenous: Immediate (within seconds to minutes) as electrolytes and fluid are directly infused into the bloodstream.
Duration of Action	Intravenous: Duration depends on infusion rate and renal clearance; typical effects last for the duration of infusion and for 2-4 hours post-infusion for electrolyte balance.

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	Contraindicated in patients with severe renal impairment (GFR < 30 mL/min) due to risk of hyperkalemia. For GFR 30-50 mL/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 mL/min.
Liver impairment	Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Pediatric use	Weight-based dosing: 20-30 mL/kg as a single intravenous infusion, administered at a rate not exceeding 5 mL/kg/hour. Maximum total volume: 1000 mL. Adjust based on clinical status and serum electrolytes.
Geriatric use	Elderly patients may require reduced infusion rates (2-5 mL/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ISOLYTE E IN PLASTIC CONTAINER (ISOLYTE E IN PLASTIC CONTAINER).

Breastfeeding	ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
Teratogenic Risk	ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.